Haemonetics (NYSE:HAE) Price Target Raised to $74.00 at JPMorgan Chase & Co.

Haemonetics (NYSE:HAE) had its price target hoisted by JPMorgan Chase & Co. from $62.00 to $74.00 in a report issued on Friday,Benzinga reports. They currently have a neutral rating on the medical instruments supplier’s stock.

A number of other equities analysts also recently commented on the company. Wall Street Zen upgraded Haemonetics from a “hold” rating to a “buy” rating in a report on Saturday, December 6th. BTIG Research restated a “buy” rating and issued a $88.00 price target on shares of Haemonetics in a report on Friday, November 21st. Citigroup decreased their price objective on shares of Haemonetics from $78.00 to $64.00 and set a “buy” rating for the company in a research note on Tuesday, October 7th. Needham & Company LLC raised their target price on shares of Haemonetics from $68.00 to $78.00 and gave the company a “buy” rating in a research note on Friday, November 7th. Finally, Barrington Research upped their price target on shares of Haemonetics from $86.00 to $90.00 and gave the stock an “outperform” rating in a research report on Friday, November 7th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Haemonetics presently has a consensus rating of “Moderate Buy” and a consensus target price of $80.90.

Haemonetics Price Performance

HAE opened at $83.46 on Friday. Haemonetics has a 1 year low of $47.31 and a 1 year high of $87.32. The company’s 50 day simple moving average is $65.38 and its 200 day simple moving average is $64.45. The stock has a market capitalization of $3.91 billion, a PE ratio of 24.40, a P/E/G ratio of 1.59 and a beta of 0.30. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.03 and a current ratio of 1.64.

Haemonetics (NYSE:HAE) last posted its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $1.27 earnings per share for the quarter, topping analysts’ consensus estimates of $1.12 by $0.15. Haemonetics had a net margin of 12.67% and a return on equity of 27.22%. The company had revenue of $327.32 million for the quarter, compared to the consensus estimate of $311.61 million. During the same quarter last year, the firm posted $1.12 earnings per share. Haemonetics’s revenue was down 5.3% on a year-over-year basis. Haemonetics has set its FY 2026 guidance at 4.800-5.00 EPS. As a group, sell-side analysts expect that Haemonetics will post 4.55 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the stock. EverSource Wealth Advisors LLC raised its stake in shares of Haemonetics by 2,640.0% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier’s stock valued at $31,000 after purchasing an additional 396 shares in the last quarter. GAMMA Investing LLC lifted its holdings in Haemonetics by 59.4% during the 2nd quarter. GAMMA Investing LLC now owns 443 shares of the medical instruments supplier’s stock worth $33,000 after buying an additional 165 shares during the last quarter. Quarry LP grew its position in shares of Haemonetics by 63.4% in the 1st quarter. Quarry LP now owns 495 shares of the medical instruments supplier’s stock worth $31,000 after acquiring an additional 192 shares in the last quarter. UMB Bank n.a. increased its holdings in shares of Haemonetics by 91.7% in the 2nd quarter. UMB Bank n.a. now owns 669 shares of the medical instruments supplier’s stock valued at $50,000 after acquiring an additional 320 shares during the last quarter. Finally, Versant Capital Management Inc raised its position in shares of Haemonetics by 216.4% during the 3rd quarter. Versant Capital Management Inc now owns 829 shares of the medical instruments supplier’s stock valued at $40,000 after acquiring an additional 567 shares in the last quarter. 99.67% of the stock is owned by institutional investors and hedge funds.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.